RxDoctor Payments DataLook up a doctor →

Jeffrey Turner, MD

Nephrology · New Haven, CTNPI 1881915601

Payments from drug & device makers

$1,302,941in general payments, 2019–2025

Across 387 payments — averaging $3366.77 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Regeneron$311K
  • Bayer$256K
  • Vertex$229K
  • Boehringer Ingelheim Pharma GmbH & Co.kg$203K
  • Boehringer Ingelheim International GmbH$167K
  • AstraZeneca$88K
  • plus $49K from 4 others
$3,032in research payments, 2019–2025

Across 10 payments — averaging $303.21 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Regeneron$2K
  • Lundbeck LLC$1K

What the payments were for

  • Travel & lodging$80058%
  • Food & beverage$57642%

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,302,941 in reported general payments places this provider in the 95th percentile of 144 nephrology providers in Connecticut.

See all nephrology providers in Connecticut

Medicare billing

Part B allowed, 2024
$69,713
Medicare patients
186
Services billed
533

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
JardianceEmpagliflozin14$22,092
LokelmaSodium Zirconium Cyclosilicate16$14,668
Sevelamer Carbonate28$8,069
Calcitriol33$711
Torsemide16$494
Bumetanide13$479
Oxycodone Hcl16$452
Lidocaine-PrilocaineLidocaine/Prilocaine11$363
Carvedilol18$269
Doxazosin Mesylate13$266
Amlodipine Besylate47$263
Chlorthalidone12$251
Losartan Potassium31$244
Pantoprazole Sodium13$161
Lactulose12$117

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaLokelma$88,157$14,66816 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 144 nephrology providers in Connecticut.

Other nephrology in New Haven

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →